RxDoctor Payments Data

Jessica Eaton

Family · Tupelo, MSNPI 1679855159

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (52.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by Boehringer Ingelheim at 31.1% of the total. Reporting peaked in 2022 at $8,666 and has fallen 64.3% since, to $3,097 in 2025. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,792in general payments, 2019–2025

Across 761 payments — averaging $32.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$8K
  • Lilly USA, LLC$5K
  • Boston Scientific$2K
  • Amgen$1K
  • Novo Nordisk$1K
  • Abbott$908
  • plus $7K from 39 others

What the payments were for

  • Speaking & faculty fees$9,92540%
  • Travel & lodging$1,7657%
  • Food & beverage$13,03753%
  • Education$660%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,792 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide305$435,475
JardianceEmpagliflozin435$413,317
MounjaroTirzepatide193$215,965
Tresiba Flextouch U-200Insulin Degludec129$178,457
TrulicityDulaglutide155$175,129
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/770$142,866
Tresiba Flextouch U-100Insulin Degludec175$140,032
FarxigaDapagliflozin Propanediol121$107,807
Fiasp FlextouchInsulin Aspart (Niacinamide)87$105,425
Novolog FlexpenInsulin Aspart246$76,770
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog40$71,438
Humulin R U-500 KwikpenInsulin Regular, Human33$57,741
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog60$52,708
Repatha SureclickEvolocumab52$51,997
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog81$46,070

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp, Novolog, Novolog Mix 70-30$1,002$519,636461 claims
Boehringer IngelheimJardiance$7,707$413,317435 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$4,618$402,027392 claims
AstraZenecaFarxiga$235$107,807121 claims
BayerKerendia$473$29,77929 claims
MerckJanumet Xr, Januvia$86$19,90724 claims
AbbVieSynthroid$431$7,45098 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →